Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand,
programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently
due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately,
only a fraction of patients with advanced tumors could benefit from anti-PD-1/PD-L1
therapy, while others still worsened. The key to this point is that there are no efficient biomarkers for
screening anti-PD-1/PD-L1-sensitive patients. In this review, we aim at summarizing the latest advances of anti-PD-1/PDL1
immunotherapy and the potential predictive efficacy biomarkers to provide evidences for identifying anti-PD-1/PDL1-
sensitive patients. The present article also includes the patent review coverage on this topic.
Keywords: Efficacy, immune check-point, immunotherapy, monoclonal antibodies, predictive efficacy biomarkers, programmed
cell death 1, programmed cell death 1 ligand.
Rights & PermissionsPrintExport